
Ekso Bionics Holdings Financial Statements 2026-2011 | EKSO
Annual Financial Statements Ekso Bionics Holdings
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | 1.49 B | 645 K | 29 M | 19.7 M | 32.3 M | 72.1 M | 28 M | 107 M | 55.2 M | 74.1 M | 117 M | 142 M | 804 M | - | - |
Shares |
139 M | 138 M | 1.34 M | 13.9 M | 13 M | 12.2 M | 8.24 M | 4.79 M | 4.08 M | 2.37 M | 1.21 M | 1.26 M | 966 K | 3.14 M | - | - |
Historical Prices |
- | 10.8 | 0.48 | 2.09 | 1.52 | 2.65 | 6.13 | 5.87 | 18.6 | 31.9 | 59.7 | 107 | 143 | - | - | - |
Net Income |
-50.3 M | -72.7 M | -11.3 M | -15.2 M | -15.1 M | -9.76 M | -15.8 M | -12.1 M | -27 M | -29.1 M | -23.5 M | -19.6 M | -33.8 M | -12.3 K | - | - |
Revenue |
71.6 M | 84.4 M | 17.9 M | 18.3 M | 12.9 M | 11.2 M | 8.88 M | 13.9 M | 11.3 M | 7.35 M | 14.2 M | 8.66 M | 5.33 M | - | - | - |
Cost of Revenue |
88.7 M | 115 M | 8.41 M | 9.2 M | 6.7 M | 4.5 M | 3.81 M | 7.15 M | 7.02 M | 5.28 M | 11.3 M | 7.48 M | 3.77 M | 2.72 M | 2.34 M | - |
Gross Profit |
- | 6.84 M | 9.51 M | 9.08 M | 6.21 M | 6.75 M | 5.07 M | 6.76 M | 4.31 M | 2.07 M | 2.95 M | 1.18 M | 1.56 M | - | - | - |
Operating Income |
-37.5 M | -55.3 M | -10.5 M | -15.1 M | -15.6 M | -13.8 M | -13.3 M | -16.6 M | -27 M | -31.6 M | -27.6 M | -21.6 M | -16.8 M | -10.3 M | -14.2 M | - |
Interest Expense |
-8 K | -26 K | -1 K | 302 K | 156 K | 113 K | 139 K | 384 K | 600 K | 648 K | 16 K | 13 K | 435 K | 1.73 M | 736 K | - |
EBITDA |
22.8 M | 25.3 M | -8.85 M | -13.4 M | -14.7 M | -12.8 M | -12.2 M | -15.9 M | -25.6 M | -29.6 M | -25.9 M | -20.6 M | -16 M | -10.9 K | - | - |
Operating Expenses |
- | 20.2 M | 20 M | 24.2 M | 21.8 M | 20.6 M | 17.9 M | 23.4 M | 31.4 M | 33.4 M | 30.7 M | 22.7 M | 18.4 M | 11.4 K | - | - |
General and Administrative Expenses |
19.8 M | 24.8 M | 8.79 M | 10.7 M | 11 M | 10.7 M | 7.7 M | 7.41 M | 11.7 M | 10.7 M | 10.9 M | 7 M | 7.4 M | 10.9 K | - | - |
All numbers in USD currency
Quarterly Income Statement Ekso Bionics Holdings
| 2026-Q4 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | 3.56 M | 3.56 M | 1.35 M | 2.18 M | 1.69 M | 1.48 M | 20.3 M | 1.22 M | 17.4 M | 14.8 M | 14.1 M | 13.6 M | 13.3 M | 13.2 M | 13.1 M | 12.9 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 10.8 M | 8.35 M | 8.24 M | 6.26 M | 5.8 M | 5.8 M | 5 M | 4.71 M | 4.34 M | 63 M | 61.4 M | 60.6 M | 60.1 M | 59.9 M | 34.7 M | 25.5 M | 21.9 M | 21.9 M | 19 M | 16.2 M | 15.4 M | 15 M | 14.6 M | 102 M | 102 M | 102 M | 78.5 M | 78.5 M | 67.1 M | 22 M | 21.1 M | 21.1 M | 20.6 M | 19.1 M | 17.9 M | 5 M | 6.35 M | - | - | - | - |
Net Income |
- | -6.88 M | - | -2.07 M | -2.71 M | -2.89 M | - | -2.07 M | -2.42 M | -3.43 M | - | -3.36 M | -4.23 M | -4.39 M | - | -4.3 M | -2.98 M | -4.62 M | - | -1.96 M | -1.27 M | -3.67 M | - | 2.45 M | -11.8 M | -2.53 M | - | 206 K | -3.07 M | -6.55 M | - | -6.98 M | -7.98 M | -7.9 M | -8.98 M | -6.34 M | -5.51 M | -8.3 M | -5.58 M | -8.48 M | -5.76 M | -3.65 M | -4.64 M | -5.18 M | -5.64 M | -4.12 M | -20.2 M | 12 M | 56.1 M | -81.8 M | -6.08 K | -11.9 M | -11.9 M | -11.9 M | -1.78 K | -7.92 K | -1.25 K | -4.66 K | - | - | - | - |
Revenue |
- | 2.14 M | - | 4.13 M | 2.06 M | 3.38 M | - | 4.13 M | 4.95 M | 3.76 M | - | 4.61 M | 4.7 M | 4.12 M | - | 3.33 M | 3.46 M | 2.57 M | - | 3.05 M | 2.21 M | 1.91 M | - | 2.9 M | 66 K | 1.47 M | - | - | - | 3.62 M | - | 2.55 M | 2.97 M | 2.52 M | 2.45 M | 1.6 M | 1.87 M | 1.44 M | 2.59 M | 1.6 M | 1.55 M | 8.49 M | 1.94 M | 2.92 M | 2.11 M | 1.69 M | 1.48 M | 1.59 M | 1.2 M | 1.06 M | - | 834 K | 984 K | 696 K | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | 1.07 M | - | 1.92 M | 1.24 M | 1.57 M | - | 1.92 M | 2.31 M | 1.8 M | - | 2.15 M | 2.45 M | 2.12 M | - | 1.64 M | 1.82 M | 1.36 M | - | 1.24 M | 919 K | 675 K | - | 1.08 M | 1 M | 831 K | - | 1.57 M | 1.7 M | 2.02 M | - | 1.47 M | 2 M | 1.75 M | - | 1.05 M | 1.47 M | 1.08 M | - | 1.19 M | 1.35 M | 6.99 M | - | 2.45 M | 1.61 M | 1.29 M | - | 1.11 M | 1.15 M | 582 K | - | 533 K | 681 K | 580 K | - | - | - | - | - | - | - | - |
Gross Profit |
- | 1.07 M | - | 2.21 M | 819 K | 1.81 M | - | 2.21 M | 2.64 M | 1.95 M | - | 2.46 M | 2.25 M | 2 M | - | 1.69 M | 1.64 M | 1.21 M | - | 1.81 M | 1.29 M | 1.24 M | - | 1.81 M | 1.26 M | 637 K | - | 1.75 M | 1.56 M | 1.6 M | - | 1.08 M | 967 K | 767 K | 777 K | 544 K | 396 K | 352 K | 843 K | 403 K | 203 K | 1.5 M | -194 K | 468 K | 502 K | 403 K | 554 K | 480 K | 45 K | 480 K | - | 301 K | 303 K | 116 K | - | - | - | - | - | - | - | - |
Operating Income |
- | -5.62 M | - | -2.64 M | -3.98 M | -3.44 M | - | -2.64 M | -2.34 M | -3.26 M | - | -2.93 M | -4.28 M | -4.45 M | - | -3.65 M | -3.23 M | -4.24 M | - | -2.79 M | -3.35 M | -3.14 M | - | -2.42 M | -3.09 M | -4.78 M | - | -3.79 M | -5.1 M | -4.91 M | - | -6.09 M | -7.18 M | -8.61 M | - | -7.07 M | -8.46 M | -8.14 M | - | -6.87 M | -7.4 M | -6.64 M | - | -5.18 M | -5.64 M | -4.09 M | - | -3.73 M | -4.31 M | -3.89 M | -6.08 K | -1.67 M | -2.71 M | -3.15 M | -1.78 K | -7.92 K | -1.25 K | -4.66 K | - | - | - | - |
Interest Expense |
- | -13 K | - | -2 K | -8 K | -6 K | - | -2 K | - | 57 K | - | 3 K | -30 K | 112 K | - | 34 K | 29 K | 27 K | - | 24 K | 27 K | 26 K | - | 23 K | 38 K | 52 K | - | 88 K | 107 K | 121 K | - | 145 K | 160 K | 163 K | - | 165 K | 198 K | 119 K | - | -1.61 M | 1.63 M | 2.99 M | - | 4 K | 3 K | 3 K | - | 3 K | 3 K | 427 K | - | 170 K | 674 K | 639 K | - | - | - | - | - | - | - | - |
EBITDA |
- | -5.16 M | - | -2.64 M | - | -3.06 M | - | - | - | -2.85 M | - | - | - | -4.03 M | - | -3.02 M | -3.23 M | -4.01 M | - | -2.01 M | -3.35 M | -3.14 M | - | -1.96 M | -3.07 M | -4.77 M | - | -3.73 M | -5.04 M | -4.88 M | - | -5.98 M | -7.1 M | -8.57 M | - | -5.75 M | -7.59 M | -7.7 M | - | -5.48 M | -6.49 M | -6.2 M | - | -4.53 M | -5.22 M | -3.89 M | - | -3.2 M | -3.98 M | -3.73 M | -6.08 K | -1.33 M | -2.48 M | -3.04 M | -1.78 K | -7.92 K | -1.25 K | -4.66 K | - | - | - | - |
Operating Expenses |
- | 6.69 M | - | 4.85 M | 4.79 M | 5.25 M | - | 4.85 M | 4.97 M | 5.21 M | - | 5.39 M | 6.54 M | 6.45 M | - | 5.34 M | 4.87 M | 5.45 M | - | 4.6 M | 4.64 M | 4.37 M | - | 4.23 M | 4.35 M | 5.42 M | - | 5.54 M | 6.66 M | 6.51 M | - | 7.18 M | 8.15 M | 9.38 M | - | 7.61 M | 8.86 M | 8.49 M | - | 7.27 M | 7.6 M | 8.14 M | - | 5.65 M | 6.14 M | 4.5 M | - | 4.21 M | 4.36 M | 4.37 M | 6.08 K | 1.97 M | 3.01 M | 3.27 M | 1.78 K | 7.92 K | 1.25 K | 4.66 K | - | - | - | - |
General and Administrative Expenses |
- | 4.06 M | - | 2.31 M | 2.25 M | 2.55 M | - | 2.31 M | 2.01 M | 2.25 M | - | 2.18 M | 2.79 M | 3.21 M | - | 2.71 M | 2.16 M | 2.9 M | - | 2.29 M | 2.14 M | 1.98 M | - | 1.71 M | 1.94 M | 2.19 M | - | 1.57 M | 2.12 M | 2.32 M | - | 2.78 M | 2.83 M | 3.74 M | - | 2.41 M | 2.48 M | 2.54 M | - | 2.32 M | 2.46 M | 3.49 M | - | 1.56 M | 1.87 M | 1.66 M | - | 1.47 M | 1.81 M | 2.07 M | 4.17 K | 752 K | 969 K | 1.13 M | 50 | 88 | 25 | 157 | - | - | - | - |
All numbers in USD currency
Main types of financial statements Ekso Bionics Holdings EKSOFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Ekso Bionics Holdings plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Haemonetics Corporation
HAE
|
$ 102.85 | 0.95 % | $ 4.85 B | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Microbot Medical
MBOT
|
$ 1.44 | 0.34 % | $ 65.9 M | ||
|
The Cooper Companies
COO
|
$ 70.64 | 1.31 % | $ 14.1 B | ||
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
Repligen Corporation
RGEN
|
$ 169.61 | 1.72 % | $ 9.54 M | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
AtriCure
ATRC
|
$ 52.46 | 7.5 % | $ 2.5 B | ||
|
Glaukos Corporation
GKOS
|
$ 180.35 | 0.46 % | $ 10.3 B | ||
|
Harvard Bioscience
HBIO
|
$ 8.0 | 0.06 % | $ 355 M | ||
|
STAAR Surgical Company
STAA
|
$ 23.58 | 2.01 % | $ 1.17 B | ||
|
STERIS plc
STE
|
$ 226.83 | 0.83 % | $ 22.3 B | ||
|
Predictive Oncology
POAI
|
- | - | $ 31.1 M | ||
|
iRhythm Technologies
IRTC
|
$ 123.43 | 0.77 % | $ 3.95 B | ||
|
AngioDynamics
ANGO
|
$ 15.47 | 0.09 % | $ 642 M | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
ICU Medical
ICUI
|
$ 166.29 | 0.07 % | $ 4.1 B | ||
|
InfuSystem Holdings
INFU
|
$ 12.18 | 0.33 % | $ 252 M | ||
|
Merit Medical Systems
MMSI
|
$ 88.57 | 0.24 % | $ 5.24 B | ||
|
Envista Holdings Corporation
NVST
|
$ 27.59 | 0.73 % | $ 4.64 B | ||
|
Pro-Dex
PDEX
|
$ 61.75 | 1.92 % | $ 203 B | ||
|
Baxter International
BAX
|
$ 25.57 | 0.86 % | $ 13.1 B | ||
|
Pulse Biosciences
PLSE
|
$ 54.71 | 3.85 % | $ 3.69 B | ||
|
Stereotaxis
STXS
|
$ 1.39 | 0.72 % | $ 126 M | ||
|
ResMed
RMD
|
$ 229.19 | 0.12 % | $ 33.4 B | ||
|
Intuitive Surgical
ISRG
|
$ 369.83 | 0.28 % | $ 132 B | ||
|
electroCore
ECOR
|
$ 9.21 | 2.03 % | $ 78.1 K | ||
|
Milestone Scientific
MLSS
|
$ 0.47 | 1.08 % | $ 38.6 M | ||
|
West Pharmaceutical Services
WST
|
$ 342.73 | 0.03 % | $ 24.8 B | ||
|
BioLife Solutions
BLFS
|
$ 35.53 | 1.27 % | $ 1.7 B | ||
|
Alcon
ALC
|
$ 72.08 | 0.3 % | $ 35.5 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 11.43 | 1.24 % | $ 2.28 B | ||
|
Masimo Corporation
MASI
|
- | - | $ 9.59 B | ||
|
Repro Med Systems
KRMD
|
$ 3.22 | 1.21 % | $ 149 M | ||
|
Nephros
NEPH
|
$ 4.18 | 0.95 % | $ 44.4 M | ||
|
LeMaitre Vascular
LMAT
|
$ 80.49 | 0.22 % | $ 1.82 B | ||
|
OraSure Technologies
OSUR
|
$ 3.58 | 2.27 % | $ 263 M | ||
|
Becton, Dickinson and Company
BDX
|
$ 187.62 | 0.05 % | $ 54 B | ||
|
Retractable Technologies
RVP
|
$ 0.71 | 1.24 % | $ 21.3 M | ||
|
Teleflex Incorporated
TFX
|
$ 139.96 | 0.35 % | $ 6.25 B | ||
|
Utah Medical Products
UTMD
|
$ 70.71 | 0.05 % | $ 229 M |